Company News: Johnson & Johnson, PriCara, Novartis and Merck KGaA

Share this article:
Johnson & Johnson's PriCara launched PrescribeResponsibly.com, a website for healthcare professionals on appropriate and responsible prescribing of opioid analgesics including case studies, sections about the role of genetics in pain and response to opioid drugs and info about the importance of considering these factors in prescribing. PriCara makes Duragesic, Ultram ER and Nucynta.
 
Three January New England Journal of Medicine studies showed that oral medications for multiple sclerosis from Novartis and Merck KGaA reduce relapse and worsening of the neurological disease. Patients who took the drugs had higher rates of infections, though. Novartis has applied for US approval of FTY720, while Merck KGaA's Merck Serono unit must resubmit its application for cladrabine after receiving an FDA refuse-to-file letter.
Share this article:

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.